Global Prenatal Genetic Testing Market, By Technology {Diagnostics Methods, Screening Methods}, Screening Techniques (Carrier Screening, Sequential Screening, and Maternal Serum Quad Screening), Diseases (Alzheimer's Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease, Rare Diseases, Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers), Product (Products, Consumables, Assay Kits, Reagents, Disposables, Instruments, Next Generation Sequencing Systems, Polymerase Chain Reaction Instruments, Microarrays, Ultrasound Devices, Other Instruments, Services) – Industry Trends and Forecast to 2030.
Prenatal Genetic Testing Market Analysis and Size
Genetic testing in newborns is greatly preferred by parents and is in higher demand, especially in the current times. Increased initiatives by the government to raise awareness associated with congenital disabilities and genetic defects in babies, particularly in developing economies, enhance the demand for prenatal genetic testing. U.S., China, and Japan are widely using prenatal genetic testing technology, which is now being followed by other developing economies.
Data Bridge Market Research analyses that the prenatal genetic testing market, which was USD 9,969.2 million in 2022, would rise to USD 29,042.3 million by 2030 and is expected to undergo a CAGR of 14.3% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Prenatal Genetic Testing Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Technology {Diagnostics Methods, Screening Methods}, Screening Techniques (Carrier Screening, Sequential Screening, and Maternal Serum Quad Screening), Diseases (Alzheimer's Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease, Rare Diseases, Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers), Product (Products, Consumables, Assay Kits, Reagents, Disposables, Instruments, Next Generation Sequencing Systems, Polymerase Chain Reaction Instruments, Microarrays, Ultrasound Devices, Other Instruments, Services)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbott (U.S.), Siemens Healthineers AG (Germany), Quidel Corporation (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Danaher. (U.S.), B.D. (U.S.), Chembio Diagnostics (U.S.), Trinity Biotech plc (Ireland), Instrumentation Laboratory (U.S.), Nova Biomedical (U.S.), PTS Diagnostics (U.S.), Sekisui Diagnostics (U.S.), Thermo Fisher Scientific (U.S.), DiaSorin S.p.A (Italy), AccuBioTech Co., Ltd. (China), Meridian Bioscience (U.S.), GeneSTAT Molecular Diagnostics, LLC (U.S.), Terumo Corporation (Japan) and Grifols, S.A (Spain)
|
|
Market Opportunities
|
|
Market Definition
Prenatal genetic testing is a medical test conducted to diagnose all types of genetic complications or abnormalities before birth during pregnancy. The gene present in the DNA sequence can be identified directly through sequencing or through various other genetic testing methods. Prenatal genetic testing is very useful in identifying congenital disabilities that arise due to hereditary and genetic disorders in the family history.
Global Prenatal Genetic Testing Market Dynamics
Drivers
- Increasing Rate of Genetic Disorders
The rising prevalence rate of genetic diseases and disorders is one of the primary factors boosting the market's growth. For instance, the growing incidence of diabetes in the family history directly boosts the market growth rate. Furthermore, several other genetic diseases such as Edward syndrome, Down syndrome, and Patau syndrome and an increasing geriatric population base susceptible to chronic diseases will rapidly enhance the market growth. Thus, this factor boosts market growth.
- Higher Technological Advancements in Prenatal genetic testing
Increasing product design advancements and quality improvement are major parameters that enhance the market's growth. For instance, Avellino Labs announced the launch of AvaGen, the genetic eye test, in the U.S. in 2021. It is designed to help identify a patient's risk of keratoconus and other corneal dystrophies. These initiatives by major market players are anticipated to boost growth. Thus, this factor boosts market growth.
Opportunities
- Increasing Demand for Cell-Free DNA in Maternal Plasma Tests
The cell-free DNA in maternal plasma tests segment is in higher demand and is boosting market growth. It is increasingly being used in identifying the risk of genetic disorders in prenatal care through numerous genetic analyses. Technological advancements now have extended the range of testing to whole-genome sequencing, and they can detect several additional chromosomal anomalies, such as sex chromosomal abnormalities and microdeletions. Thus, this factor is helping in improving the market growth.
Restraints/Challenges
- High Cost of Prenatal Genetic Testing
The high cost of prenatal genetic testing is very expensive, which impedes the market growth. Currently, the R&D of prenatal genetic tests are more costly than traditional medicines as they need advanced toosl and techniques. Therefore, these factors hamper the market growth.
This prenatal genetic testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prenatal genetic testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2021, MedGenome Labs launched its direct-to-consumer category with the brand name Genessense. It will offer specialized, evidence-based genetic screening tests that can be ordered online through the Genessense website or other e-commerce platforms.
- In 2021, Avellino Labs announced the launch of AvaGen, the Genetic Eye Test, in the U.S. It is manufactured to identify the risk of patients from developing keratoconus and other corneal dystrophies.
Global Prenatal Genetic Testing Market Scope
The prenatal genetic testing market is segmented on the basis of technology, screening techniques, diseases, end user and product. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Technology
- Diagnostics Methods
- Polymerase Chain Reaction
- Array Comparative Genomic Hybridization (Acgh)
- Fluorescence In Situ Hybridization (FISH)
- Screening Methods
- Non-Invasive Prenatal Tests
- Maternal Serum Screening
Screening Techniques
- Carrier Screening
- Sequential Screening
- Maternal Serum Quad Screening
Diseases
- Alzheimer's Disease
- Cancer
- Cystic Fibrosis
- Sickle Cell Anemia
- Duchenne Muscular Dystrophy
- Thalassemia
- Huntington's Disease
- Rare Diseases
- Other Diseases
End User
- Hospitals
- Clinics
- Diagnostic Centers
Product
- Consumables
- Assay Kits And Reagents
- Disposables, Instruments
- Next Generation Sequencing Systems
- Polymerase Chain Reaction Instruments
- Microarrays
- Ultrasound Devices
- Other Instruments
- Services
Prenatal Genetic Testing Market Regional Analysis/Insights
The prenatal genetic testing market is analyzed and market size insights and trends are provided by technology, screening techniques, diseases, end user and product as referenced above.
The countries covered in the prenatal genetic testing market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the prenatal genetic testing market because of the huge base of healthcare facilities, major market players in this region, the increasing pregnancy rate, and the growing number of research activities.
Asia-Pacific is expected to witness significant growth due to the rise in government initiatives to promote awareness, increasing research activities in the region and wide availability of massive untapped markets. Also, increasing availability of the well-established infrastructure towards awareness in early screening of genetic disorders and the increasing demand for quality healthcare in the region boost the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The prenatal genetic testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for prenatal genetic testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the prenatal genetic testing market. The data is available for historic period 2011-2021.
Competitive Landscape and Prenatal Genetic Testing Market Share Analysis
The prenatal genetic testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to prenatal genetic testing market.
Some of the major players operating in the prenatal genetic testing market are:
- Abbott (U.S.)
- Siemens Healthineers AG (Germany)
- Quidel Corporation (U.S.)
- F. Hoffman-La Roche Ltd. (Switzerland)
- Danaher. (U.S.)
- B.D. (U.S.)
- Chembio Diagnostics (U.S.)
- Trinity Biotech plc (Ireland)
- Instrumentation Laboratory (U.S.)
- Nova Biomedical (U.S.)
- PTS Diagnostics (U.S.)
- Sekisui Diagnostics (U.S.)
- Thermo Fisher Scientific (U.S.)
- DiaSorin S.p.A (Italy)
- AccuBioTech Co., Ltd. (China)
- Meridian Bioscience (U.S.)
- GeneSTAT Molecular Diagnostics, LLC (U.S.)
- Terumo Corporation (Japan)
- Grifols, S.A (Spain)
SKU-